TB/Non-TB Mycobacterial Infections
Cohort Study: TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area.
16 Mar, 2022 | 08:44h | UTC
Review: Mycobacterial skin infection.
14 Mar, 2022 | 00:59h | UTCMycobacterial skin infection – Current Opinion in Infectious Diseases
RCT: In children with nonsevere, drug-susceptible tuberculosis, treatment for 4 months is noninferior to treatment for 6 months.
10 Mar, 2022 | 11:03h | UTCNews Release: Treatment length reduced for children with tuberculosis – University College London
Commentary on Twitter
Completing 6 months of treatment for tuberculosis in children is a challenge. In this open-label trial involving 1204 children in sub-Saharan Africa and India, 4 months of antituberculosis therapy was noninferior to 6 months of therapy. https://t.co/zkD4URWMru pic.twitter.com/LFR6ZzTKgs
— NEJM (@NEJM) March 9, 2022
Pictorial Review | Extrapulmonary tuberculosıs: an old but resurgent problem.
9 Mar, 2022 | 08:33h | UTCExtrapulmonary tuberculosıs: an old but resurgent problem – Insights into Imaging
New CDC interim guidance recommends a 4-month Rifapentine-Moxifloxacin regimen to treat drug-susceptible pulmonary tuberculosis.
27 Feb, 2022 | 22:49h | UTCRelated:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO Guideline: Screening for Tuberculosis Disease
New WHO Recommendations to Prevent Tuberculosis
CDC Guidelines for the Treatment of Latent Tuberculosis Infection
Guideline: Treatment of Drug-Resistant Tuberculosis
The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis
Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives
Guidelines for the Management of TB in Adults Living with HIV
Commentary on Twitter
Clinicians: @CDC_TB released interim guidance on a new regimen to treat #TB disease. Learn more about the 4-month regimen containing rifapentine, moxifloxacin, isoniazid, and pyrazinamide for people with drug-susceptible pulmonary TB disease in the U.S.: https://t.co/eOcR34tYJu pic.twitter.com/EFGMwAwN7c
— MMWR (@CDCMMWR) February 25, 2022
Essay: Tuberculosis in times of COVID-19.
15 Feb, 2022 | 10:16h | UTCTuberculosis in times of COVID-19 – Journal of Epidemiology & Community Health
Related:
Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.
Global tuberculosis progress reversed by COVID-19 pandemic.
How COVID is derailing the fight against HIV, TB and malaria.
How COVID hurt the fight against other dangerous diseases
World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis
Tuberculosis and Covid-19: Fighting a deadly syndemic
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments.
11 Feb, 2022 | 08:29h | UTC
Systematic Review: Video-observed therapy vs. directly observed therapy in patients with tuberculosis.
9 Feb, 2022 | 08:35h | UTCVideo-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis – American Journal of Preventive Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Our latest publication on @AmJPrevMed : Video-Observed Therapy Versus Directly Observed Therapy in Patients With Tuberculosis. Implementation of VOT improved medication adherence and bacteriological resolution compared with that of DOT in TB patients.https://t.co/xcWzrxLbHB? pic.twitter.com/4ldYJ2umd7
— Bang Truong (@bangphd_epi) December 13, 2021
Cluster-Randomized Trial: A multicomponent diagnostic strategy (on-site molecular testing for tuberculosis, guided restructuring of clinic workflows, and monthly feedback of quality metrics) significantly improved the rates of a confirmed diagnosis of tuberculosis within 14 days after presentation.
8 Feb, 2022 | 08:43h | UTCMulticomponent Strategy with Decentralized Molecular Testing for Tuberculosis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
A cluster-randomized trial in 20 Ugandan health centers compared a multicomponent TB strategy with routine care. The intervention led to greater numbers of patients being tested for, receiving a diagnosis of, and being treated for confirmed TB. https://t.co/PcJDC1I0CY pic.twitter.com/AT99QVOn2S
— NEJM (@NEJM) December 28, 2021
RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.
26 Jan, 2022 | 01:58h | UTC
Commentary on Twitter
In this 2-year study, data showed that electronic directly observed therapy (eDOT) was as effective as traditional in-person DOT for ensuring high adherence to treatment of tuberculosis disease. @CDC_TB @nycHealthy @ColumbiaMed https://t.co/yTrU1JRuwn pic.twitter.com/QXthE4d266
— JAMA Network Open (@JAMANetworkOpen) January 20, 2022
Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.
11 Jan, 2022 | 01:33h | UTC
Commentary on Twitter
In @NEJM today, @TerezaKasaeva @doctorsoumya and I write about
Covid-19’s devastating impact on tuberculosis care & offer suggestions for recoveryhttps://t.co/buOEOPVWwM pic.twitter.com/BfOK3X3MuU
— Madhu Pai, MD, PhD (@paimadhu) January 5, 2022
AAP Clinical Report | Tuberculosis Infection in Children and Adolescents.
2 Dec, 2021 | 09:58h | UTCTuberculosis Infection in Children and Adolescents: Testing and Treatment – Pediatrics
Global tuberculosis progress reversed by COVID-19 pandemic.
19 Nov, 2021 | 10:51h | UTCGlobal tuberculosis progress reversed by COVID-19 pandemic – The Lancet Respiratory Diseases
Related:
How COVID is derailing the fight against HIV, TB and malaria.
How COVID hurt the fight against other dangerous diseases
World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis
Tuberculosis and Covid-19: Fighting a deadly syndemic
Commentary on Twitter
NEWS—Global #tuberculosis progress reversed by #COVID19 pandemic
"Due to the delayed effects from #COVID19, #tuberculosis deaths are projected to rise again in 2022 while the world readjusts to a new normality and services resume."
Read more here: https://t.co/tWVXswZsvs
— The Lancet Respiratory Medicine (@LancetRespirMed) November 3, 2021
WHO Report: Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic.
15 Oct, 2021 | 02:30h | UTCReport: Global tuberculosis report 2021
Commentary: Tuberculosis deaths rise for 1st time in years, due to COVID – Associated Press
Commentary on Twitter (thread – click for more)
? WHO's Global TB Report reveals deaths from #tuberculosis rise for the first time in more than a decade due to the #COVID19 pandemic.
1.5 million people died in 2020 & the number will continue to rise unless urgent action is taken ?https://t.co/RFmWYIelhq #EndTB pic.twitter.com/33G7sI8K2J
— World Health Organization (WHO) (@WHO) October 14, 2021
Systematic review: Pretomanid for tuberculosis.
6 Oct, 2021 | 08:51h | UTCPretomanid for tuberculosis: a systematic review – Clinical Microbiology and Infection
Related:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO announces updated definitions of extensively drug-resistant tuberculosis
How COVID is derailing the fight against HIV, TB and malaria.
15 Sep, 2021 | 09:01h | UTCHow COVID is derailing the fight against HIV, TB and malaria – Nature
Related:
How COVID hurt the fight against other dangerous diseases
World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis
Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis.
10 Sep, 2021 | 05:18h | UTCInvited Commentary: The incalculable costs of tuberculosis
Commentaries on Twitter
A strong eeconomic case for ending TB – trillions of dollars in savings. Cost of not acting now is going to be too expensive! @StopTB https://t.co/ffLVTeqOkj
— Suvanand Sahu (@SahuSuvanand) September 5, 2021
Failure to achieve the SDG tuberculosis mortality target by 2030 will lead to profound economic and health losses:
$3·0 trillion will be lost if the target is not met until 2045!!
Sachil Silva, Nim Pathy, @mikereidmd @DrEricGoosby @RifatAtun https://t.co/ipm5vj62IQ @LancetGH pic.twitter.com/fPHDW5eJWE
— Madhu Pai, MD, PhD (@paimadhu) September 3, 2021
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
9 Jun, 2021 | 08:12h | UTCOriginal Guideline: WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment – Drug-Resistant Tuberculosis Treatment
Commentary on Twitter
???@ERSpublications
WHO guidelines on the treatment of drug-resistant TB contain the latest recommendations on shorter or longer all oral treatment regimens for patients with drug-resistant TB, including the medicines to be used& supportive measures https://t.co/qeeftVYdYN pic.twitter.com/4NKNNjz3Gh— Antibiotic Steward ???Bassam Ghanem (@ABsteward) June 8, 2021
Practice changing | A four-month rifapentine regiment with moxifloxacin is noninferior to the standard 6-month regimen in the treatment of tuberculosis.
6 May, 2021 | 08:56h | UTCCommentary: Four-month TB treatment matches six-month standard of care – Aidsmap
Review and Algorithm: Tuberculosis and the Heart
31 Mar, 2021 | 03:07h | UTCTuberculosis and the Heart – Journal of the American Heart Association
Commentary on Twitter
Tuberculosis cardiac involvement is frequent. A systematic review and a new algorithm for CV TB is now available! https://t.co/QhzUCVWIxA @adribaran @JosePatricioLop @SIAC_cardio pic.twitter.com/AuotMOUjR0
— JAHA (@JAHA_AHA) March 29, 2021
M-A: Incidence and prevalence of tuberculosis in incarcerated populations
25 Mar, 2021 | 08:09h | UTCCommentary: Tuberculosis in prisons: an unintended sentence? – The Lancet Public Health
Commentary on Twitter (thread – click for more)
1/n
Our new study is published for World TB Day in @TheLancetPH investigating the prevalence and incidence of tuberculosis among incarcerated populations! https://t.co/ZXQ2pQk97K pic.twitter.com/ah4ydI3uXr— Leo Martinez (@LeoMarti_EpiTB) March 22, 2021
[Press release – not published yet] Trial of multi drug-resistant TB treatment ends enrolment early after independent board indicates new regimen is superior
25 Mar, 2021 | 08:10h | UTC
Commentary on Twitter
Promising news improving treatment #MDR #TB https://t.co/Lxjb7LBofy Translating findings to available drugs & diagnostics back it up will be key pic.twitter.com/YGp8d9ixww
— Michael Marks (@dr_michaelmarks) March 24, 2021
WHO Campaign | World Tuberculosis Day 2021: The Clock Is Ticking
24 Mar, 2021 | 08:16h | UTCWorld Tuberculosis Day 2021: The Clock Is Ticking – World Health Organization
WHO Guideline: Screening for Tuberculosis Disease
24 Mar, 2021 | 08:13h | UTCSee also: WHO Operational Handbook on Systematic Screening for Tuberculosis – World Health Organization
World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis
24 Mar, 2021 | 08:19h | UTCSee also: 1.4 million with tuberculosis, lost out on treatment during first year of COVID-19 – United Nations